Actinium Pharmaceuticals Showcases ATNM-400's Multi-Tumor Efficacy at Key International Cancer Conference

Unveiling the Potential of ATNM-400 in Cancer Treatment

Actinium Pharmaceuticals, Inc., a pioneer in innovative targeted radiotherapies, is poised to make headlines at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Set to take place from October 22-26, 2025, this prestigious gathering will showcase the first-ever preclinical findings for Actinium's groundbreaking product, ATNM-400, particularly in the treatment of non-small cell lung cancer (NSCLC).

ATNM-400 represents a significant advancement in cancer therapy as a first-in-class Actinium-225 antibody radioconjugate. This promising radiotherapy candidate demonstrates potential efficacy not only against NSCLC but also against prostate cancer—two of the most prevalent cancer types with a collective incidence exceeding 500,000 new cases in the U.S. annually.

Addressing Critical Needs in Lung Cancer Treatment

NSCLC accounts for about 85% of all lung cancer cases, contributing to its status as the leading cause of cancer-related deaths globally. While advancements have been made with EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib (Tagrisso), the unfortunate reality is that nearly all patients develop resistance within a few years, leaving them with limited treatment options.

However, exciting preclinical results are set to be discussed at the conference, indicating that ATNM-400 exhibits strong anti-tumor activity in models with EGFR-mutant NSCLC. Notably, it has shown the ability to overcome resistance to osimertinib, which is a major unmet clinical need in the oncology field. The synergy of ATNM-400 in combination with osimertinib could represent a transformational shift for patients battling relapsed or refractory diseases, offering them renewed hope where options have been scarce.

In a multicenter, single-arm Phase 2 trial analyzing the efficacy of osimertinib combined with radiotherapy for advanced EGFR-mutant NSCLC, a median progression-free survival of 32.3 months was reported. This finding marks a substantial improvement when compared to the 20-month median progression-free survival seen with osimertinib alone.

Conference Presentation Details

The presentation titled "ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, demonstrates potent anti-tumor activity and overcomes osimertinib resistance in lung cancer models" is scheduled for Saturday, October 25, 2025, during Poster Session C. Attendees can preview the abstract online at 12 PM E.T. on October 22, 2025, via the AACR journal, Molecular Cancer Therapeutics.

Broader Indication Potential

Initially developed for prostate cancer treatment, ATNM-400’s broader potential is noteworthy. Unlike PSMA-targeting agents such as 177Lu-PSMA-617, which have been widely utilized in current prostate cancer therapies, ATNM-400 aims at a distinct receptor that plays a critical role in tumor progression and treatment resistance. This property ensures its effectiveness even in cases where PSMA is low or resistant, addressing a considerable gap in existing therapeutic options. In fact, preclinical studies have shown that ATNM-400 can surpass resistance mechanisms post-ARPI therapy, displaying enhanced efficacy in combination with treatments like enzalutamide, further improving patient outcomes.

CEO Sandesh Seth expressed enthusiasm about the data indicating that ATNM-400 can successfully tackle osimertinib resistance in NSCLC, a challenging area in oncology. He emphasized the potential of ATNM-400 to deliver superior outcomes compared to standard therapies and highlighted its promise for patients with treatment-refractory conditions.

This exciting scenario opens doors for ATNM-400 to emerge as a transformative therapy that extends its reach beyond prostate cancer to address other significant conditions in the realm of solid tumors.

Conclusion

As the conference approaches, all eyes will be on Actinium Pharmaceuticals as it shares groundbreaking data on ATNM-400. With its potential to revolutionize treatment paradigms for both NSCLC and prostate cancer, ATNM-400 signifies a hopeful advancement in the relentless fight against cancer, promising better survival rates and quality of life for patients grappling with these formidable diseases.